Accused of “warming the market” for a new Eylea indication ... GSK scolded after complainant flags 'shocking error' in prescribing information Bayer appealed all the breaches in the PMCPA ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

About AVT06 AVT06/AVT29 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept ... Please click here for full Prescribing Information for SELARSDI. About Teva Teva ...

AVT06/AVT29 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept ... Please click here for full Prescribing Information for SELARSDI. Teva Pharmaceutical Industries ...

About AVT06AVT06/AVT29 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept ... Please click here for full Prescribing Information for SELARSDI.

PULSAR in wAMD and PHOTON in DME/diabetic retinopathy (DR) are double-masked, active-controlled pivotal trials that were conducted in multiple centers globally. In both trials, patients were ...

This component supplier has expeditiously responded to FDA requests for information. The CRL did not identify any issues with respect to the safety or efficacy of EYLEA HD, the usability of the ...